- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04075175
Evaluate the Safety Pharmacokinetics of a Human Monoclonal Antibody S315 Against Diphtheria Toxin in Healthy Subjects (S315)
A Phase 1 Study in Healthy Subjects to Evaluate the Safety and Pharmacokinetics of a Human Monoclonal Antibody (mAb) S315 Against Diphtheria Toxin
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21225
- PAREXEL Early Phase Clinical Unit
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Capable of giving written informed consent and able to effectively communicate with the Investigator and study personnel. A signed informed consent document (ICD) must be on file prior to initiating the screening procedures.
Willing and able to complete all study requirements, restrictions, visits and procedures.
- Age 18 to 55 years, inclusive.
- Weight 50 kg to 90 kg, inclusive.
- Systolic blood pressure less than 140 mmHg and diastolic less than 90 mmHg on two separate readings at least one minute apart.
Women of child bearing potential, defined as all women physiologically capable of becoming pregnant must agree not to become pregnant and must use a method of birth control during the entire study.
Women of non-child bearing potential may be included. Women are considered post-menopausal and not of childbearing potential if, they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile or have had surgical total hysterectomy or tubal ligation at least six weeks ago.
- Males of reproductive potential must use a barrier method of contraception during the course of the study.
Screening laboratory values must meet the following criteria:
- White blood cell (WBC) 3.5 - Upper Limit of Normal (ULN)
- Platelets > 100,000/mm3
- Hemoglobin ≥ Lower Limit of Normal (LLN)
- Creatinine ≤ ULN
- Aspartate Aminotransferase (AST) ≤ ULN
- Alanine Aminotransferase (ALT) ≤ ULN
- Alkaline Phosphatase ≤ ULN
- Bilirubin ≤ ULN
- HgbA1c
Exclusion Criteria:
1. Previous receipt of humanized or human monoclonal antibody whether licensed or investigational.
2. History of or any current medical condition that could compromise the safety of the participant in the study, as determined by the Investigator.
3. History of suicidal behavior within 12 months prior to screening.
4. Donated blood or plasma within 60 days prior to dosing.
5. Clinically significant gastrointestinal, cardiovascular, neurologic, psychiatric, substance abuse, metabolic, renal, hepatic, respiratory, inflammatory, or infectious disease, as determined by the Investigator.
6. Drug or alcohol abuse within previous 12 months or a positive test at screening and at Day -1 within 24 hours of study product administration.
7. History of a previous severe allergic reaction with generalized urticaria, angioedema or anaphylaxis.
8. Physical finding on examination considered clinically significant such as murmur (other than functional), hepatosplenomegaly, lymphadenopathy or focal neurological deficit.
9. Urinalysis positive for > trace protein, > 5 Red Blood Cell (RBC)/hpf or > 5 WBC/hpf.
10. Positive serology for HIV antibody, Hepatitis C Virus (HCV) antibody or Hepatitis B surface antigen at screening.
11. Positive serum pregnancy test during screening or within 24 hours of study product administration, or an unwillingness to undergo pregnancy testing.
12. Pregnant within 6 months or breast-feeding within 3 months prior to screening.
13. Receipt of licensed vaccine containing diphtheria toxoid (Td, Tdap, pneumococcal conjugate vaccines, meningococcal conjugate vaccines) within the last year.
14. Treatment with another investigational drug or other intervention within 30 days from screening.
15. Any other condition that in the opinion of the investigator would jeopardize the safety or rights of the subject participating in the study.
16. Safety laboratory abnormalities at Screening or Day -1, which are clinically significant as determined by the Investigator.
17. Tobacco, e-cigarettes, and/or nicotine use within 30 days prior to screening confirmed by urine cotinine test.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: S315 human monoclonal antibody
5 cohorts of 8 subjects each randomized 6:2 (S315:Placebo (0.9% Sodium Chloride)) with escalation of a fixed dose of S315
|
Human monoclonal antibody against Diphtheria Toxin
|
Placebo Comparator: 0.9% sodium chloride (NaCl)
5 cohorts of 8 subjects each randomized 6:2 (S315:Placebo(0.9%
Sodium Chloride)) with escalation of a fixed dose of S315
|
Placebo 0.9% Sodium Chloride (NaCl)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The number of Participants with adverse events as assessed by the Division of Microbiology and Infectious Diseases (DMID) Adult Toxicity Table (Draft revised November 2007) adapted by the Division of Microbiology and Infectious Diseases, NIAID, NIH.
Time Frame: Day -1 through Day 60
|
Adverse events assessed for safety
|
Day -1 through Day 60
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serial measurements of S315 concentration in the serum.
Time Frame: Day 1 pre-dose and Day 1, Day 2, Day 4, Day 8, Day 15, Day 22, day 29, Day 43 and Day 60 post-dose
|
Pharmacokinetics
|
Day 1 pre-dose and Day 1, Day 2, Day 4, Day 8, Day 15, Day 22, day 29, Day 43 and Day 60 post-dose
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ronald Goldwater, MD, Parexel
- Study Director: John Z Sullivan-Bólyai, MD, MPH, MassBiologics of the University of Massachusetts
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MBL-DIPH-19-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diphtheria
-
Hillel Yaffe Medical CenterRecruitingDiphtheria-Tetanus-acellular Pertussis VaccinesIsrael
-
GlaxoSmithKlineCompletedDiphtheria-Tetanus-acellular Pertussis VaccinesFinland, Australia, Spain, Italy, Canada, Czechia
-
ABO Holdings, Inc.Active, not recruitingTetanus, Diphtheria and Acellular Pertussis VaccinationUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedPertussis | Tetanus | Diphtheria | Diphtheria Immunisation | Tetanus Immunisation | Clostridium Difficile ImmunisationMali
-
Women and Infants Hospital of Rhode IslandNot yet recruitingVaccine Exposure During Pregnancy | Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination | Non-birthing Partner Vaccination in Pregnancy
-
GlaxoSmithKlineTerminatedDiphtheria-Tetanus-Acellular PertussisColombia
-
Sanofi Pasteur, a Sanofi CompanyCompletedDiphtheria, Tetanus and PertussisSpain
-
Institute of Arthritis ResearchLouisiana State University Health Sciences Center in New Orleans; Brigham Young...Not yet recruitingPre-Eclampsia | Diphtheria, Tetanus and Pertussis Vaccine ReactionUnited States
-
GlaxoSmithKlineCompletedDiphtheria-Tetanus-acellular Pertussis VaccinesRussian Federation
-
CanSino Biologics Inc.Active, not recruitingDiphtheria, Tetanus and Acellular PertussisChina